Oliver Sol
Chief Tech/Sci/R&D Officer at AC IMMUNE SA
Profile
Oliver Sol is currently working as the VP & Head-Clinical Development at AC Immune SA. Previously, he worked as the Clinical Director at Exonhit and as the Director-Medical & Regulatory Affairs at Eurobio-Scientific SA. Dr. Sol holds a doctorate degree from Université de Paris XI Paris Sud.
Oliver Sol active positions
Companies | Position | Start |
---|---|---|
AC IMMUNE SA | Chief Tech/Sci/R&D Officer | - |
Former positions of Oliver Sol
Companies | Position | End |
---|---|---|
EUROBIO SCIENTIFIC | Chief Tech/Sci/R&D Officer | - |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | Chief Tech/Sci/R&D Officer | - |
Training of Oliver Sol
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
AC IMMUNE SA | Health Technology |
EUROBIO SCIENTIFIC | Health Technology |
Private companies | 2 |
---|---|
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | Health Technology |
Université de Paris XI Paris Sud | Consumer Services |
- Stock Market
- Insiders
- Oliver Sol